Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
Andreas Wollenberg(Vrije Universiteit Brussel), Lynda Spelman(Veracity Clinical Research), Charles Lynde(University of Toronto), Emma Guttman‐Yassky(Rockefeller University), Hidehisa Saeki(Nippon Medical School), Michael J. Cork(University of Sheffield), Norito Katoh(Kyoto Prefectural University of Medicine), Alexandra Kuznetsova(Boston Children's Hospital), Margitta Worm(Freie Universität Berlin), Leon Kircik(University Medical Center), J.‐P. Lacour(Institut Gustave Roussy), T.N. Jensen(Leo Pharma (Denmark)), Louise Abildgaard Steffensen(Leo Pharma (Denmark)), Aleksandra Lesiak(Medical University of Lodz), Yves Poulin(ENT and Allergy), B K Bang(Leo Pharma (Denmark)), Pedro Herranz(Hospital Universitario La Paz), Andrew Blauvelt(Oregon Medical Research Center), S.H. Cho(Catholic University of Korea), Ketty Peris(Agostino Gemelli University Polyclinic), Eric L. Simpson(Oregon Health & Science University), Marie Louise Østerdal(Leo Pharma (Denmark))
Cited by 590
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
EAACI Food Allergy and Anaphylaxis Guidelines: diagnosis and management of food allergy
|Allergy|2014|1.4k
World Allergy Organization Anaphylaxis Guidance 2020
|World Allergy Organization Journal|2020|1.1k
Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology
|Allergy|2014|1k
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
|Nature Genetics|2012|1k